Investment Thesis

, necessitating a reassessment of the position size.

Competitive Moat

Amgen's competitive moat is primarily derived from its intangible assets, including a strong brand reputation and a portfolio of patented therapies, which create high switching costs for healthcare providers. The company has established itself as a leader in key therapeutic areas, making it difficult for new entrants to compete effectively. Over the next 5-10 years, this advantage is likely to remain intact, although competitive threats from biosimilars and emerging biotech firms could challenge its market position.

Growth Engine

Amgen’s future revenue growth is expected to stem from a combination of expanding its existing product lines and launching new therapies. The company has a substantial total addressable market (TAM) in oncology, cardiovascular diseases, and autoimmune disorders, which is projected to grow due to increasing prevalence and demand for innovative treatments. The company’s recent focus on strategic partnerships and collaborations enhances its pipeline and market access, ensuring organic growth while maintaining market share in its established segments.